Nivolumab plus ipilimumab (N+I) in patients (pts) with colorectal cancer (CRC) with BRCA1/2 alterations (alts): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study

Authors

Olatunji B. Alese
Michael Rothe
Elizabeth Garrett-Mayer
Carolyn Anne Carrera
Evan P. Pisick
Timothy Lewis Cannon
Justin Tyler Moyers
Mehmet Akce
Jimmy J. Hwang
Mridula Krishnan
Ankoor Biswas, Advocate Health - MidwestFollow
Majd Chahin
Meredith McKean
Davendra Sohal
Tilak Kumar Sundaresan
Uma Suryadevara
Muhammad Usman
Abigail Gregory
Susan Halabi
Richard L. Schilsky

Recommended Citation

Alese OB, Rothe M, Garrett-Mayer E, et al. Nivolumab plus ipilimumab (N+I) in patients (pts) with colorectal cancer (CRC) with BRCA1/2 alterations (alts): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. Journal of Clinical Oncology. 2026;44(2_suppl):127-127. doi:10.1200/JCO.2026.44.2_suppl.127

Affiliations

Aurora Cancer Care, Milwaukee

Type

Abstract